TIKOMED Granted Orphan Medicinal Drug Designation for ILB® for the Treatment of Amyotrophic Lateral Sclerosis by the European Commission
TFS International AB (TFS) Appointed CRO Representative for TIKOMED's Phase 2 Study in Clinical Islet Transplantation
Shadow Lake Group Appointed Strategic Advisor and Business Development Representative for the Licensing Process of IBsolvMIR® in Canada
TIKOMED Granted Permission for Phase 2 Clinical Trial in Islet Cell Transplantation by the Swedish Medical Product Agency
Tikomed to Initiate ALS Clinical Trial for Which the UK Medicines and Healthcare Products Regulatory Agency Has Granted Permission
Tikomed Granted Permission for Clinical Trial in ALS by the Swedish Medical Product Agency and Ethical Review Board.
TikoMed Ready to Initiate Clinical Studies for Amyotrophic Lateral Sclerosis (ALS), Glaucoma, Alzheimer's, Traumatic Brain Injury (TBI), Stroke and Fibroproliferative Conditions (Scarring)